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Abstract
Background: The external validity, or generalizability, of trials and guidelines has been considered poor in the 
context of multiple morbidity. How multiple morbidity might affect the magnitude of benefit of a given treat-
ment, and thereby external validity, has had little study. Objective: To provide a method of decision analysis 
to quantify the effects of age and comorbidity on the probability of deriving a given magnitude of treatment 
benefit. Design: We developed a method to calculate probabilistically the effect of all of a patient’s comorbidities 
on their underlying utility, or well-being, at a future time point. From this, we derived a distribution of possible 
magnitudes of treatment benefit at that future time point. We then expressed this distribution as the probability 
of deriving at least a given magnitude of treatment benefit. To demonstrate the applicability of this method of 
decision analysis, we applied it to the treatment of hypercholesterolaemia in a geriatric population of 50 indi-
viduals. We highlighted the results of four of these individuals. Results: This method of analysis provided 
individualized quantifications of the effect of age and comorbidity on the probability of treatment benefit. The 
average probability of deriving a benefit, of at least 50% of the magnitude of benefit available to an individual 
without comorbidity, was only 0.8%. Conclusion: The effects of age and comorbidity on the probability of 
deriving significant treatment benefits can be quantified for any individual. Even without consideration of other 
factors affecting external validity, these effects may be sufficient to guide decision-making.
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(RCTs) and systematic reviews. Relevance depends on 
external validity, or generalizability (i.e. whether the 
results can be applied to a definable group of patients in 
a particular setting in clinical practice and to individual 
patients) [1]. For example, how should a 75-year-old 
man with lung cancer, diabetes, hypertension, and atrial 
fibrillation (AF) be advised as to the benefits of treating 
hypercholesterolaemia, in his case?
There is concern amongst clinicians that external 
validity is often poor [1], particularly in the situation 
of multiple comorbidity [2–5]. Issues that may poten-
tially affect external validity include the setting of the 
Introduction
In making treatment decisions, doctors and patients must 
take into account relevant randomized clinical trials 
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trial, characteristics of randomized patients, differences 
between the trial protocol and routine practice, outcome 
measures and follow-up, and adverse effects of treatment 
[1]. Another issue affecting external validity, one that has 
received little attention, is how qualitative aspects of treat-
ment outcomes vary in different populations.
The fact that, in the context of comorbidity, the 
outcome of intercurrent death abolishes any treatment 
benefit has been recognized [6]. Decision analyses have 
indicated that treatments should be more conservative 
when longevity is limited [7,8]. However, intercurrent 
non-fatal comorbidity also has an effect; it reduces, 
rather than necessarily abolishes, the magnitude of any 
treatment benefit. 
For an example of the effect of non-fatal comorbidity, 
imagine a treatment that prevents an illness resulting in 
breathlessness, which limits mobility to 50 metres. The 
treatment would provide enormous benefit to an athletic 
individual. If, on the other hand, an individual is limited 
to a mobility of 75 m by a comorbidity, such as arthritis, 
the treatment would still be beneficial, but less so. If a 
patient’s mobility is already restricted to 50 m or less, the 
magnitude of treatment benefit disappears. 
Another example of treatment benefit is the prevention 
of seizures allowing an individual to maintain their driv-
ing licence. This benefit is not available to an individual 
already unable to drive, on account of comorbidity. The 
prevention of seizures still has a benefit to that individual, 
but its magnitude is reduced by a quantum.
Although all patients are at risk of intercurrent death 
and impairment from comorbidity, this is particularly true 
for patients with known impairments and comorbidities 
[9-12]. This has been shown for both elderly (mean age 
79 years) [9] and middle-aged (≥45 years) [10] patients. In 
practice, patients with comorbidities are commonly seen 
[5]. The probability of treatment benefit for these patients 
depends not only on the treatment-specific probability 
but also on the probability of remaining sufficiently well, 
despite their comorbidities, to be in a position to derive a 
significant magnitude of treatment benefit.
We have previously shown mathematically that 
comorbidities limit the benefits of treatments [13]. Pre-
vious studies of comorbidity, using quality-adjusted life 
years or the like as a metric of benefit, also indicate a 
reduction in treatment benefit. Cost–benefit studies 
have shown significant increases in this ratio in the con-
text of comorbidity [14–16].
In this paper, we demonstrate that knowledge of a 
patient’s age and comorbidities allows an estimation of 
their probability of being in a given state of ‘wellness’ at a 
future date. From this estimation, we show that the prob-
ability of deriving given magnitudes of treatment benefit 
can be estimated. We provide a method to perform these 
calculations and demonstrate the principles of the method 
using the demonstration case in our introduction. We 
provide, in greater detail, examples of the application of 
this method to individual patients and to a population. 
These examples demonstrate how, in practical terms, 
the method might be applied, and how it might generate 
meaningful information. We propose simple variations of 
the method that might readily be applied in practice.
Information regarding benefit in terms of probability 
is important, as it is the way in which data are presented 
in trial reports. Furthermore, in contrast to the purpose 
of cost–benefit studies, which is primarily economic, the 
expression of information in terms of an individual’s prob-
ability of treatment benefit is fundamental to that patient’s 
assessment of, and consent to, therapies [17,18].
Methods
This study was approved by the Ethics Committee of 
The Royal Adelaide Hospital.
Our analysis is essentially a decision tree analysis, 
whereby all of the potential outcomes of a treatment are 
calculated [19]. For example, disease a might have out-
comes a1, a2, a3, etc. Each of these outcomes has its own 
probability and utility state (a quantification of ‘wellness’ 
lying between 0 [death] and 1 [complete well-being], as 
determined a priori) [19]. Traditionally, the mean util-
ity under different treatments is calculated and thereby 
the relative effects of the treatments are determined, i.e. 
the magnitude of the difference in treatment benefit is 
equivalent to the mean utility difference. 
We extended the traditional analyses by individually 
factoring in the potential outcomes of other comor-
bidities. Rather than the number of outcomes being 
limited to the number of outcomes associated with the 
treatment in question, we generated all of the combi-
nations of possible outcomes taking other comorbidities 
into consideration. Thus, for comorbidity b, there may 
be outcomes b1 and b2, and for comorbidity c, there 
may be outcomes c1 and c2. Thereby, the number of 
potential outcomes for a patient with disease a and also 
comorbidities b and c, increases to include all of the pos-
sible combinations, e.g. a1,b1,c1, a1b1c2, etc. Just as in a 
traditional analysis, each outcome has its own a priori 
determined, or calculated, probability and utility states. 
In this paper, we only studied the benefits of treat-
ments, and so our analysis excluded adverse outcomes 
(side effects, complications), due to a treatment. Thus, if 
a3 above represented an adverse outcome from the treat-
ment of disease a, it would appear in a traditional decision 
analysis, but not in our analysis. Because we studied the 
outcome at a given time point rather than the accumu-
lated benefit, we did not need to consider the order in 
which various outcomes might occur.
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Rather than determining an average value, we chose 
to compare the distribution of benefit in the comorbid 
state with the distribution of benefit in the absence of 
comorbidity. The comorbid states vary in utility from 
0% to 100%. We expressed the data in terms of the prob-
ability of utility being at least a given value. Though this 
calculation (the complementary cumulative distribution 
function of the quality of outcome) is cumbersome, it 
is mathematically simple and readily performed with a 
computer programme. Thus, for any patient, it becomes 
possible to state the probability of benefit for any given 
value. We appreciated that the minimum level of benefit 
that is considered ‘significant’ or ‘worthwhile’ is arbitrary 
and could, for example, be determined by consensus of 
professional bodies for guidelines, and/or by individuals 
for their own cases. This level could vary between [20] 
and within individuals for different  conditions. We con-
sidered that, rather than diminishing the validity of this 
calculation, the validity is enhanced by this incorpora-
tion of personal values.
This method requires no additional assumptions to 
those of traditional decision analyses. The same proba-
bilities and utility states used in other decision analyses/
applications can be used as inputs. In fact, any idiosyn-
cratic values may be chosen as inputs for utility states 
and for the probabilities of outcomes – the results would 
be valid for that hypothetical circumstance. The valid-
ity of the method (as for any decision analysis tool) is 
independent of the validity of the inputs. For there to be 
inter-observer agreement as to the validity of calculated 
results for particular individuals, however, there must 
be, as in all decision analyses, agreement with regard to 
the validity of the inputs.
Demonstration of method
A 75-year-old male patient with lung cancer, diabetes, 
hypertension, and AF would like to better understand 
the benefit of starting statin therapy for hypercholester-
olaemia. His healthcare professional has explained that 
it should lower his risk of having a myocardial infarc-
tion (MI). Evidence from large RCTs demonstrates that 
reducing cholesterol levels with a statin might decrease 
the 5-year risk of an MI by one-third [21–24]. For this 
male, a cardiovascular (CV) risk calculator [25] indicates 
that the 5-year risk of MI is high at 15%, and so, before 
considering any complicating factors, such as comorbidity, 
statin therapy in this case offers a 5% probability of benefit. 
Additionally, the average impairment score of a non-fatal 
MI has been reported to be 25% [26]. Therefore, before 
considering other factors and ignoring the possibility of 
fatal MI, the magnitude of treatment benefit is 25%.
However, as the patient is on treatment for lung cancer, 
and the 5-year outcome for survival is 50% [27], the 5% 
probability of benefit is subdivided such that there is a 
2.5% probability of deriving benefit from statin treatment 
and of being alive (magnitude of benefit 25%), and a 2.5% 
probability of benefit, but also of being dead from can-
cer (magnitude of benefit reduced to 0%). In the absence 
of cancer treatment, the probability of death might be 
60%, such that there is only a 2% probability of the 25% 
benefit.
If the patient is alive despite the cancer, there is also 
the consideration of the impairment of the cancer and 
its treatment. A usual method of assessing the magnitude 
of treatment benefit in the context of impairment from 
other conditions is to reduce the benefit in proportion 
[26,28,29]. If, therefore, the average impairment of the 
cancer and its treatment at 5 years is estimated at 40% 
[26], the magnitude of treatment benefit is reduced by 
40% (the benefit of MI prevention is now 25% of 60%, i.e. 
15%, rather than 25% of 100%). This reflects the fact that 
the patient is not in a position to derive the full benefit 
of MI prevention and, for example, may not derive the 
full benefit of freedom from fatigue and/or breathless-
ness. There is, thus, a partial retention of treatment benefit 
compared with the above-mentioned extreme situation of 
intercurrent death. The 2.5% probability of benefit from 
statin treatment, whilst being alive with cancer, now has 
a magnitude of only 15%, this accompanying the 2.5% 
probability of 0% benefit, derived with intercurrent death 
from the cancer.
The patient also has AF, and treatment (aspirin) and 
risk scoring (CHADS
2
 score 3) indicate that over 5 years 
there is a 20% probability of stroke [30–33], resulting in 
an average 50% impairment [26]. Consideration of this 
comorbidity results in the 2.5% probability of statin treat-
ment benefit, whilst being alive with cancer treatment, 
being further subdivided. There is now a new category of 
benefit, the prevention of MI in an individual alive with 
both cancer and a stroke. The probability of this outcome 
is 0.5% (20% of 2.5%) and the relevant magnitude of ben-
efit is 25% (the benefit of MI prevention) of the utility 
state of an individual with cancer and stroke (50% of 60%). 
This calculation results in a treatment benefit magnitude 
of 7.5%. Thus, the original 5% probability of benefit mag-
nitude of 25% – the probability and magnitude of benefit 
of treatment in the absence of comorbidities – has been 
subdivided and reduced to the following:
 • 2.5% probability of benefit + death from cancer (mag-
nitude of benefit = 0%)
 • 0.5% probability of benefit + alive with cancer + stroke 
(magnitude of benefit = 7.5%)
 • 2.0% probability of benefit + alive with cancer with-
out stroke (magnitude of benefit = 15%)
The patient can therefore be advised that his comorbidi-
ties have affected his probability of benefit from statin 
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therapy, such that he has a 2.5% probability of deriving 
at least 7.5% benefit, a 2% probability of deriving at least 
15% benefit, and a 0% probability of deriving greater 
than 15% benefit (and thus also 0% probability of deriv-
ing the full original 25% benefit magnitude). This can 
be expressed graphically (Figure 1). The patient can be 
advised that the 7.5–15% magnitude of benefit corre-
sponds to the prevention of asymptomatic, or minimally 
symptomatic, ischaemic heart disease, in an individual 
without comorbidity [26].
Any of the patient’s other comorbidities and risks can 
be added to the calculation, providing there are esti-
mates for the probability of the outcomes and their 
respective impairment values. Each new consideration 
progressively adds precision to, and lowers, the estima-
tions of magnitudes of treatment benefit. Alternatively, 
the analysis may be simplified, such that only the major 
comorbidity, lung cancer, is considered. 
Application of method
Patient selection 
We obtained a subset of patient data from a larger project 
investigating the interactions between diseases, comor-
bidities, and treatments. For this larger project, we 




















Figure 1 The probability of deriving any absolute level of 
benefit from statin therapy, with or without the consideration of 
comorbidities, for our demonstration case (75-year-old male with lung 
cancer, diabetes, hypertension and atrial fibrillation).
Table 1 Characteristics of the four selected patients.
Patient Age, years Sex Comorbidities
1 65 Male Osteoporosis, hypertension, hypercholesterolaemia diabetes, dementia
2 80 Female Osteoporosis, hypertension, hypercholesterolaemia, fracture, chronic obstructive pulmonary disease
3 89 Female Osteoporosis, hypertension, hypercholesterolaemia, fracture
4 83 Male Osteoporosis, hypertension, hypercholesterolaemia, lumbar plexopathy, cancer, atrial fibrillation
enrolled 50 consecutive patients seen in the Geriatric 
Clinic of the Royal Adelaide Hospital who satisfied the 
inclusion criterion of being on drug therapy for osteo-
porosis, hypertension, and hypercholesterolaemia, to 
serve as our study population. As this study is a decision 
analysis applied to a subset of individuals, the size of the 
parent sample is not of importance to this work. 
In this study, we highlighted four patients, deliber-
ately chosen on account of their different comorbidity 
characteristics, to demonstrate the feasibility of applying 
the above method of comorbidity analysis to individual 
patients. There is no claim that these patients’ results can 
be generalized to other, dissimilar, individuals. We chose 
the patients to demonstrate the different ways in which 
comorbidity may affect treatment benefit, i.e. by death 
or impairment, and also to demonstrate the effect of an 
increased number of comorbidities. Any of the 50 patients 
could well have been highlighted, but the inter-individ-
ual differences might have been more subtle.
Table 1 summarizes the characteristics of the four 
selected patients. Patient 1 was 65 years old with initial 
impairment from diabetes (10%) and dementia (25%), and 
had an estimated 5-year dementia impairment of 60%. 
Patient 2 was 80 years old with minimal initial impair-
ment from a previous fracture (3%) and mild chronic lung 
disease (10%). Patient 3 had even less initial impairment 
(3% from fracture) but, at 89 years of age, had a higher 
risk of death. Patient 4 was 83 years old with significant 
initial impairment from a lumbar plexopathy (40%) and 
cancer (15%), and at risk of stroke from AF. All four 
patients also had the three conditions required for inclu-
sion in the study sample, i.e. they were being treated for 
hypercholesterolaemia, osteoporosis, and hypertension. 
Statin efficacy and comorbidity data
After analysis of the 50 participants’ medical histories, we 
calculated (by reference to the literature [21–24]) their indi-
vidual expected 5-year risk of fatal and non-fatal MI, with 
or without therapy for hypercholesterolaemia. This calcu-
lation, based on the premise of no comorbidity, resulted in 
a value comparable to that of our demonstration case, as 
described in the first paragraph of the introduction.
Analogous to the consideration of comorbidity in the 
demonstration case, we then factored into our analysis the 
range of possible outcomes due to the effects of age, which, 
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for the purposes of this paper, was treated as a comor-
bidity; the hypertension and osteoporosis present as per 
the selection criteria, and other comorbidities including 
AF, dementia, obstructive lung disease, cancer, diabetes, 
blindness, deafness, arthritis and  Parkinson’s disease. 
For age, we estimated the 5-year risk of death [34]; 
for AF and hypertension, we estimated the 5-year risk of 
stroke [30–33,35–37]; for osteoporosis, we calculated the 
5-year risk for hip fracture [38–42]; and for dementia [43], 
obstructive lung disease [44], cancer [27,45], and heart fail-
ure [46–49], we estimated the 5-year risks of progression 
and death. The risk of incident dementia was also consid-
ered [50]. For pragmatic reasons, we took the conservative 
course of assuming no progression in impairment or risk 
of death for diabetes, blindness, deafness, arthritis, and Par-
kinson’s disease. Similarly, we did not consider the patients’ 
other comorbidities, apart from severe neurological deficits 
in two patients (lumbar plexopathy and spinal infarction).
We assumed that the rate of accumulation of risk, and 
treatment benefit [21], was constant, and extrapolated the 
results of studies to 5 years as necessary. We chose 5 years as 
our time frame as this is commonly used in trials and in the 
quantification of CV risk [51]. As far as possible, all proba-
bilities were checked to be based on censored data (i.e. data 
from patients who died during the relevant studies were 
not considered), and/or from trials in which the death rate, 
and thereby any potential effect of censoring, was small.
For the treatment of hypercholesterolaemia and the 
comorbidities, we accorded efficacies as generously as 
the literature would allow, with no reduction on account 
of the age and comorbidities of our patients per se. We 
considered the efficacies of different statins and different 
antihypertensives to be equivalent, but we differentiated 
the efficacy of antiresorptives (bisphosphonates/hormo-
nal preparations) from that of supplemental calcium and 
vitamin D (Table 2).
Magnitude of treatment benefit data
We referred to the Guides to the Evaluation of Permanent 
Impairment (‘the Guides’) [26] for the quantification of the 
impairment of MI in the absence of comorbidity. This value 
became the magnitude of treatment benefit in the absence 
of comorbidity (‘the baseline benefit’). To translate ‘impair-
ment’ to ‘utility’, ‘utility’ may be considered 1 − ‘impairment’. 
The baseline treatment benefit was 100% for prevention of 
fatal MI and 25% for prevention of non-fatal MI. 
We used the same source for the quantification of the 
impairment due to comorbidities. When impairment 
due to any other condition was uncertain, we used the 
lower end of the range quoted by the Guides.
The Guides, as also recommended elsewhere [28,29], 
use a multiplicative method of combining impair-
ments. In this mathematical method of determining 
the weighting of multiple pathologies, the weighting 
of impairment is multiplied by pre-existing well-being 
(1 – impairment). For example, what is considered to be 
40% impairment in a perfectly well person is reduced to 
32% impairment in an individual already 25% impaired. 
This prevents a sum of weightings exceeding 100% 
(equivalent to death). This multiplicative method also 
determines the magnitude of treatment benefit. If, as 
above, a potential impairment is reduced from 40% to 
32%, the magnitude of benefit of a treatment that pre-
vents this disability is also reduced from 40% to 32%.
Combining outcomes
In the context of multiple comorbidities, there are mul-
tiple possible outcomes, each with its own probability. 
When considering all the combinations of possible out-
comes, we took the parsimonious option of considering 
them to be mutually independent. 
We took care not to double count impairments 
and risks. For example, we subtracted any component 
attributable to dementia and heart disease from age-re-
lated mortality on account of our separate calculation 
of mortality due to dementia and heart disease. When 
an impairment could have possibly been due to more 
than one condition, we recorded it under one head-
ing only, i.e. the one we considered most likely to be 
correct. Thus, for our patients, we constructed a table 
Table 2 Examples of treatment efficacies obtained from the literature.
Condition Outcome risk Treatment Risk reduction, % References
Hypercholesterolaemia Myocardial infarction Statin 50 [19–22]
Hypertension Cerebrovascular accident Antihypertensive 33 [26]
Osteoporosis Hip fracture Antiresorptive agent 50 [32,35]
Calcium ± vitamin D 20 [34,35]
Heart failure Death β-blocker 33 [41]
ACE inhibitor 33 [42]
ACE inhibitor + β-blocker 50 [41,42]
Atrial fibrillation Cerebrovascular accident Anticoagulation 60 [30]
Antiplatelet 22 [30]
ACE, angiotensin-converting enzyme.
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documenting all of their treatments and comorbidities 
with the corresponding initial impairments (at the time 
of enrolment), and the probabilities for impairments and 
death at 5 years (Supplementary Methods 1). An overall 
summary of our patient sample is provided in Table 3.
Analysis
Distribution of utility (well-being) 
We first calculated the ‘comorbidity effect’ as the prob-
ability of being sufficiently able (i.e. not disabled/dead 
on account of other conditions), to derive at least a speci-
fied proportion of the baseline treatment benefit. More 
mathematically, we calculated ‘the probability of hav-
ing other impairment less than or equal to that which 
allows the patient to derive at least a specified proportion 
of the baseline treatment benefit’ (see Supplementary 
Methods 2). 
In order to determine the first probability, we consid-
ered each individual in terms of the chances of death/
disability from other conditions, i.e. without reference 
to the condition addressed by that treatment, in this 
case treated hypercholesterolaemia. We considered all 
of the possible combinations of other impairments. 
We calculated the probability and impairment magni-
tude of each combination. We could then calculate the 
probability of having impairment less than or equal to a 
given proportion (the complementary cumulative dis-
tribution function of the quality of outcome). Thus, for 
each patient, we could create a graph of their chances, 
with the x-axis showing the magnitude of benefit 
from 0% to 100% of baseline, and the y-axis showing 
the probability of deriving at least that magnitude of 
benefit. 
Table 3 Demographics of study population.
Demographic




Number of medications, mean (range) 10.4 (3–19)
Number of comorbidities, mean (range)* 7 (3–10)
Residential status, n
 Own home 42
 Nursing home 8
Mean initial impairment, % 57.45
5-year conditional impairment, % (if alive) 66.73
5-year mortality, % 49.05
Median life expectancy, years ~5
Charlson comorbidity index, mean (range) 3.34 (0–7)
Charlson age-adjusted comorbidity index, mean (range) 6.94 (4–11)
*All of the patients had at least the three comorbidities necessary for 
inclusion in the study, i.e. treated hypercholesterolemia, osteoporosis, 
and hypertension.  
Distribution of treatment benefit 
To quantify treatment benefit, we multiplied the above 
first probability (the comorbidity effect) by each indi-
vidual’s baseline efficacy of the studied treatment (i.e. 
the probability of benefit ignoring the effects of comor-
bidity). This is just a multiple of the first probability (the 
complementary cumulative distribution function), but 
each individual has a different multiplier as each indi-
vidual has a different CV risk, and thereby different 
baseline efficacy of treatment.
We also interpreted these results in absolute terms, the 
x-axis in this presentation showing the various degrees 
of absolute benefit i.e. 0–100% impairment benefit in 
absolute terms. This corresponds to the expression of 
benefit in the demonstration case.
Sensitivity analyses 
We subjected our results to sensitivity analyses, changing 
our data regarding the baseline probability or efficacy of 
treatment up or down by 50%, and by eliminating the 
effect of age-related mortality. Using our assumption of 
a constant rate of accumulation of hazards and benefit, 
we also calculated the effects of reducing the time frame 
of analysis from 5 years to 1, 2, 3, or 4 years.
In addition, we performed sensitivity analyses adjusting 
impairment scores and disease progression in a similar way to 
that for treatment efficacy (for disease progression we allowed 
for only a reduction). If the original impairment was less than 
50%, we adjusted this up and down by 50%. However, for high 
impairment scores (over 50%), to avoid yielding an impair-
ment score greater than 100% and to maintain symmetry 
with low impairment scores, we adjusted utility.  Figure 2 is a 
graph of this transformation, indicating the sensitivity limits 



























Figure 2 Transformation of impairment scores used in the sensitivity 
analysis.
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for each impairment value. As the impairment scores might 
be considered less objective than the other inputs, we also 
performed similar analyses whereby impairment values were 
reduced further, i.e. by 75% and 90%.
Results
Benefit of statin treatment in the absence 
of comorbidity
Our patients were at high risk of MI. The average 
untreated 5-year risk of MI was 14.8%, which was 
similar to that of the demonstration case. Thus, with-
out considering comorbidity, the probability of deriving 
benefit from statin treatment was 4.9% (risk reduction 
by one-third). The magnitude of benefit was 25% for 
non-fatal MI and 100% for fatal MI. 
Distribution of utility (well-being) 
The comorbidity effect (i.e. the probability of being suf-
ficiently able [i.e. not disabled/dead on account of other 
conditions]), to derive at least a specified proportion of 
the baseline treatment benefit was different for each of 
the 50 patients. Figure 3 shows the probability distribu-
tion for each individual’s benefit of MI prevention with 


















































Figure 3 The probability for each of our 50 patients of being 
sufficiently well to be able to derive at least the specified proportion 
of the baseline impairment benefit for myocardial infarction 
prevention. The sample mean and our four selected patients’ curves 
are emphasized. Note the steep drops and long horizontal sections 
for the individual patients, which are caused by the assumption that 
any additional impairment is exactly the given average impairment, 
not a range of possible values from some unknown distribution. Were 
the literature to provide more detailed information as to this range 
in possible outcomes, then each such subset of the average outcome 
could be represented. The steep drops and long horizontal sections 
would then be broken into multiple smaller steps, such that the graphs 
would eventually become smooth decreasing curves.
statin therapy. Also shown is the mean for this sample of 
50 patients. The height of each individual intercept on the 
y-axis indicates the probability of being alive at 5 years 
(and thus the probability of deriving any benefit from treat-
ment); the intercept on the x-axis indicates the maximum 
possible state of utility (1 – impairment) for that individual 
at 5 years. This latter value was largely a function of the 
initial state.
The profile of Patient 2 indicates that he was in a posi-
tion to have the greatest probability, of the four selected 
patients, of deriving a benefit comparable with baseline 
(Figure 3). This profile reflects that he was minimally 
impaired and had a reasonably good 5-year prognosis. 
Though Patient 3 also had only mild baseline impairment, 
the probability of deriving any level of significant bene-
fit was greatly reduced by the age-related risk of death. 
Patient 1, though having a reasonable longevity chance, 
was unable to derive benefit above 45% baseline benefit 
on account of baseline impairment. The profile of Patient 
4 had more segments plotted. As each segment corre-
sponds to a discrete utility state, such an increase in the 
number of segments indicates that Patient 4 had more 
known comorbidities, and therefore, more combinations 
of comorbidity outcomes, and thereby, a greater range of 
quantifiable potential states of impairment.
Distribution of treatment benefit 
Figure 4 displays the probabilities of deriving at least a 
specified proportion of a baseline impairment benefit. 
These probabilities are low on account of both the mod-
est baseline efficacies of treatment and the reduction by 
the effect of comorbidity. Because each patient has a 









































Figure 4 The probability of deriving a specified proportion of 
a baseline impairment benefit for each of our 50 patients. This 
probability is a subdivision of the baseline efficacy. The sample mean 
and our four selected patients’ curves are emphasized.
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different baseline efficacy of cholesterol-lowering ther-
apy, on account of different CV risk, the curves are not 
identical to those of Figure 3.
Patient 4, for example, who, in the absence of comor-
bidity, would have had a 5% probability of benefit, only 
has a 3.1% probability of any benefit (where the curve 
of Patient 4 crosses the y-axis, this value having been 
reduced from 5% by the risk of death). Furthermore, there 
is only a 1.8% probability that the magnitude of benefit 
will exceed 50% of the baseline benefit. In the absence of 
comorbidity, the full 5% probability of benefit would be 
for a benefit magnitude of 100% baseline benefit. Of the 
four highlighted patients, Patient 2 had the greatest prob-
ability (1.9%) of deriving a magnitude of benefit of at least 
50% baseline (as well as a similar probability of deriving a 
magnitude of benefit of at least 60–70% baseline).
Figure 5 shows the information in terms of absolute 
benefit values for the patients. Note that, as statin effi-
cacy is, at best, less than 15%, the most likely outcome 
is no treatment benefit, and that the probability of any 
benefit is subdivided into the chance of benefit of ‘sig-
nificant’ and ‘non-significant’ magnitude. Any increase 
in the minimum magnitude of benefit deemed signif-
icant (the x-axis) decreases the probability of deriving 
that benefit.
The red section of Figure 5 corresponds to Figure 1 
from the demonstration case. For Patient 4, the proba-
bility of significant benefit becomes very small once a 
value of 12.5% is exceeded on the x-axis; i.e. the bulk of 
the modest baseline efficacy provides an absolute benefit 
magnitude between 0% and 12.5%. This range corre-
sponds to the baseline impairment of asymptomatic, or 
minimally symptomatic, heart disease.
Sensitivity analyses 
Figure 6 shows that our conclusions were robust, requir-
ing major changes to the input data to  generate major 
changes to the probability distributions. The sensitiv-
ity studies reflected the different dependence of each 
patient’s outcomes on impairment estimations and treat-
ment efficacy estimations. As the sensitivity studies 
result in complex graphs, the graph of only Patient 4 is 
shown to serve as an example.
Figure 7 shows that when considering a longer time 
frame of analysis, the effect of comorbidity in dimin-
ishing the magnitude of treatment benefit increases. 
This is to be expected, as with the passage of time, 
there is more opportunity to accumulate impairment. 
For example, in an extreme scenario of a 20-year out-
look, one would expect treatment benefit magnitude at 
that time point to be universally zero, as all our ger-
iatric patients would be expected to have died. This 
was particularly true when the comorbidity effect was 
determined more by age-related risk of death rather 
than by baseline impairment. Although there is a 
decreased comorbidity effect with shorter time, the 
baseline treatment benefit decreases commensurately. 
The benefits of treatments tend to accumulate pro-
portionately over time, and in particular this has been 
shown for statin therapy [21].
Simpler expression of results 
Rather than having a multiplicity of possible chances 
of benefit, depending upon the magnitude of treatment 
benefit considered significant, the chances can be approx-
imated to a single point estimate. One such estimate, 
applied to the chances demonstrated in  Figure 4, results 
from the combination of the probability of being alive at 
5 years and deriving any treatment benefit, with the best 
possible anticipated utility (Figure 8 upper panel). This lat-
ter variable can be further simplified to the utility state at 
time zero. This estimate results in a conservative measure 
of the effects of comorbidity.
This approximation is quite close for Patients 1, 2, and 
3, as they have fewer comorbidities. The approximation 
is less accurate and more conservative for Patient 4. For 
this patient, an alternative point estimate results from 
the use of the mean, rather than the best, anticipated 
 utility (Figure 8 lower panel).
Analogous point estimates may be obtained for the 
probability of absolute treatment benefit (corresponding 
to Figure 5).
Full patient group results
For our full sample of 50 patients, there was, on aver-
age, only approximately a 20% probability of being able 
to derive at least 50% of the magnitude of the baseline 
benefit (Figure 3). After incorporating the baseline effi-
cacy of treatment, the average probability of deriving 
at least 50% of a positive baseline impairment benefit 
was only 0.8% (Figure 4). In the absence of comorbidity 
there would have been on average a 4.9% probability of 
a benefit magnitude 100% of baseline. 
Discussion
Using data from standard sources, and without mak-
ing any new assumptions, we have presented a method 
by which the effect of comorbidity on the magnitude 
of treatment benefits can be quantified in terms of 
the change in the probability of benefit. Our exam-
ples show that there is interindividual variation in 
the effects of comorbidity, and that these effects can 
be significant, such that treatments that offer modest 
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Figure 6 Sensitivity studies for Patient 4. Adjustments, up and down, were made to estimates of treatment efficacy and impairment scores. Age-
related death, and initial impairment were removed from consideration, and disease progressions were reduced, these all being adjustments to 
mitigate the effects of coomrbidity. The main analysis refers to that shown in Figure 3.
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Figure 5 The probability of deriving any absolute level of benefit. Because the probability of any treatment benefit in any individual is at best 
around 15% (the efficacy of statin therapy), the most likely outcome of treatment is no benefit. The large blue section of each graph represents this 
probability. The remainder of each graph represents the probability of benefit from statin therapy; this is subdivided into two sections, indicating 
the probability that the benefit magnitude will (red), or will not (yellow), be significant. As one chooses a higher magnitude of benefit deemed 
significant, the probability of deriving such a benefit diminishes. The probability of benefit actually extends beyond a magnitude of 25%, but is too 
small to be observed on this scale.
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Figure 7 Sensitivity studies of the effect of changing the time span of analysis from 5 years to 1, 2, 3, and 4 years. The main analysis refers to that 
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Figure 8 Expression of data as single point estimates. Estimates were calculated using a combination of the probability of being alive at 5 years 
and deriving any treatment benefit, with the best anticipated utility for our four selected patients (upper panel). These point estimates are at the 
intersection of the horizontal and vertical lines, and are represented by the asterisks. Patient 4, for example, could have his probabilities condensed to 
a point estimate of just over a 3% chance of a benefit magnitude of at least 50% of the baseline benefit (upper panel). For Patient 4, point estimates 
(asterisks not inserted) were also calculated using the mean, rather than the best, anticipated utility (lower panel). The just over 3% chance is now for 
a benefit magnitude of only at least 42% of the baseline benefit. The solid lines in each panel represent the main analyses of this paper. The main 
analysis refers to that shown in Figure 4.
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probability and/or modest magnitudes of benefit in 
the absence of considerations of comorbidity, may 
offer very low chances of significant benefit in the 
context of comorbidity. 
Our results were obtained by accepting trial results 
and guidelines at face value, indicating that, even in the 
absence of estimations of the effects of the other factors 
that limit the external validity of trials and guidelines, 
external validity can be shown to be poor, merely by 
considering the magnitude of treatment benefit. Fur-
thermore, apart from just showing that external validity 
is poor, this consideration may provide sufficient infor-
mation to advise individual patients, who are elderly 
and/or with multiple morbidity, as to the degree to 
which trials and guidelines might overestimate their 
individual probability of significant treatment benefit. 
The consideration of the other factors affecting external 
validity would complement the use of our method.
The merit of a medical therapy is first assessed on 
the basis of the associated probability of benefit in the 
context of its risks [52]. If the probability is considered 
attractive, its cost then determines whether or not the 
therapy can be justified economically. When consider-
ing comorbidity, our method allows the reassessment of 
the probability of treatment benefit, in terms analogous 
to the original studies, so that these can be confirmed 
to be attractive prior to the consideration of the revised 
cost–benefit. Any need to refuse/not offer treatments 
on the basis of cost–benefit considerations in the con-
text of comorbidity is thereby likely to be diminished.
Our analysis of patients on statin therapy for hyper-
cholesterolaemia has demonstrated that, if only 
cardiovascular risk (i.e. no comorbidity) had been 
considered, these patients might have been judged to 
have had a good probability of benefit, in accordance 
with guidelines [53]. However, when comorbidity 
was considered, statins offered, on average, only very 
low chances of significant benefit, similar to those for 
patients with much lower cardiac risk and no comorbid-
ity. Such patients at lower cardiac risk, and with lower 
potential for benefit, would not normally be considered 
candidates for therapy [53]. 
Our patients’ anticipated benefit was assessed for a 
5-year outlook, whereas guidelines suggest a 10-year 
outlook [53]. As our patients were older individuals with 
comorbidity, their probability of benefit over a subsequent 
5-year period would be expected to be even lower, such 
that the 10-year benefit would be well below the min-
imum level of 10-year benefit thought to justify statin 
therapy [53]. Furthermore, even this minimum level is 
low; the minimum risk level is 7.5% over 10 years, such 
that the expected benefit would be approximately 2.5% 
over 10 years. Even in the best circumstances, the benefit 
of statins [54], like the benefits of other recommended 
treatments [55], are often not considered by patients [54] 
or the general public [55] to be sufficiently great to justify 
the promotion of such treatments.
We have thus shown that CV risk assessment alone 
may not provide the best measure for selecting patients 
for this therapy, but rather that such an assessment would 
be better done together with a quantitative assessment 
of the effect of comorbidity. Patients with a high car-
diac risk and a low comorbidity burden stand to gain 
the most from statins. A patient with high cardiac risk 
may still be in a position to derive significant benefit, 
despite comorbidities. The demonstration patient, and 
perhaps Patient 4, might be such individuals, depending 
upon the level of benefit magnitude deemed significant. 
Patient 2, on account of a moderately high MI risk and 
a relatively low comorbidity burden, also maintained a 
modest level of treatment benefit. Additionally, other 
patients in our sample of 50 individuals demonstrated 
even better levels of treatment benefit (Figure 4).
The opportunity to incorporate patient-centred out-
comes, engage patients in decision-making, and enhance 
physician–patient shared decision-making would be 
greater using such an assessment. This approach, like 
other decision analyses [56], cannot itself provide a 
definitive answer as to whether the probability of benefit 
justifies a given treatment. There may be guidelines, but 
individual practitioners and patients may prefer to set 
their own threshold of significant benefit and consider 
the probability themselves. 
Our method is an extension of the consideration of 
multiple competing outcomes. It has been pointed out 
that in a population at significant risk of death, the base-
line risk of any outcome is likely to be overestimated 
if risk is extrapolated from studies using censored data 
[6]. In these circumstances, the probability of any ther-
apeutic benefit is correspondingly reduced. We have 
considered how non-fatal comorbidity, an additive 
rather than a competitive entity, also restricts the benefit 
of any intervention. 
Ideally, all of a patient’s comorbidities would be 
included in an analysis using this method. For prag-
matic reasons, we limited the number of comorbidities 
and outcomes that we analysed. This rendered our 
results conservative. Further limitation of the number of 
comorbidities considered, even down to a single major 
comorbidity, provides a means by which any practi-
tioner might relatively easily apply the method without 
assistance of a mathematician or a computer programme. 
Our examples of simpler expressions of the results of 
a fuller calculation may also help with applying the 
method in practice. 
We have only studied the benefits of treatments in 
the context of comorbidity. We did not analyse costs 
and risks in the same way, but we know from previous 
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studies [14–16,57] showing a fall in cost-benefit, that, 
in the context of comorbidity, costs do not fall propor-
tionately with benefit. Furthermore, even in the absence 
of consideration of risk, treatments require a threshold 
level of benefit to be judged worthwhile [54].
The source of our impairment percentages implies 
that all impairments of the same absolute value are 
equal, and that the same pathology causes different 
incremental impairments, depending upon other con-
temporaneous impairment. This multiplicative method 
is also endorsed elsewhere [28,29]. We believe this 
relationship is rational, expressing mathematically the 
generalization that if one is unable to perform a function 
on account of impairment in one system, a similar dys-
function due to impairment in another system will be, 
to some extent, redundant. The use of different inputs 
would result in different estimates of the comorbidity 
effect, and different methods of calculating the impair-
ment of combined conditions would necessitate different 
methods for generating the probability calculations. All 
resulting estimates of the  comorbidity effect would be 
valid. Potentially, the impairment  values for all combi-
nations of conditions might be known empirically. 
If the impairments of comorbidities were to be 
regarded as combining strictly additively, the comorbid-
ity effect would disappear and trial data and guidelines 
could be applied without consideration of comorbidity. 
There is, however, no inherent justification for such an 
assumption, the shortcomings of which have previously 
been described [29]. In particular, it is not possible for the 
outcome of death to be additive [29] (if more than one 
fatal outcome is averted only one life is saved).
We assumed that all outcomes of different conditions 
are mutually independent. In general, this is a parsimo-
nious assumption, e.g. there are no data to indicate that a 
patient with osteoporosis has greater or lesser protection 
from an MI with statin therapy compared with a patient 
without osteoporosis. If there is evidence that comor-
bidities affect the outcomes of the treatment in question, 
then this can be incorporated into the initial individ-
ualized data, as we did in assessing MI and AF-related 
stroke risk, for example. Our impairment scores for 
multiple comorbidities were based on the impairment 
scores for each of the individual comorbidities. To the 
extent that the impairment resulting from individual 
comorbidities may, on account of clinical, rather than 
mathematical, interactions, be even  more severe in the 
presence of other comorbidities, our results are conserv-
ative. For example, in our demonstration case, if the 
outcome from stroke was exacerbated by the presence 
of the lung cancer, then the utility state in these cir-
cumstances would be even worse than what we have 
allowed, and, the benefit from statins would be even less. 
Any lack of independence of the probability of adverse 
outcomes of different comorbidities would increase the 
probability of impairment at both ends of the spectrum. 
Our sensitivity analyses suggest that results obtained 
using our method are likely to be robust, i.e. likely 
to withstand variations in inputs. We believe that the 
±50% sensitivity analyses that we performed for efficacy 
suffice, as these inputs are trial-based. Our sensitivity 
analyses suggest that the inputs from different sources 
for risk estimation and treatment effect would have to 
be large to change our results significantly. One could 
argue that our impairment estimates, though based 
on empirical data and taken from a recognized refer-
ence, are arbitrary and possibly inaccurate. However, 
our sensitivity analyses again indicate that a consider-
able overestimation of impairment scores is required to 
minimize the comorbidity effect. Such changes to our 
impairment scores are not only unrealistic, they would 
also cast doubt on the value of the medical interven-
tions in the first place, i.e. the impairment they prevent 
would be small. Our estimates of the effects of age and 
comorbidity may be considered conservative, as there 
are additional impairments that might have been con-
sidered. These include any impairment due to age, per 
se (i.e. only the age-related death risk was included), 
and the effects of psychosocial and unknown future 
comorbidities.
In accordance with other methods analysing the effects 
of comorbidity [14–16], our method demonstrates that 
treatments to prevent an illness in an older person with 
comorbidity are likely to be less advantageous than the 
same treatments given to a younger, otherwise healthy, 
person. Our method faces similar limitations and chal-
lenges to those of more conventional economic studies. 
These include variation in health state utilities (which 
in our source would translate to impairment values), 
concerns of fairness of treatment, and the possible under-
estimation of the individual utility of health gains when 
treatment potentials are somewhat limited [58]. To some 
extent, our method, by providing a conservative measure 
of comorbidity, might allay these concerns.
Conclusions
Many practitioners are intuitively aware of the effects of 
age and comorbidity on the probability of the benefit of 
medical treatments, and adjust patient care accordingly. 
The formal description in this paper of the relation-
ships underlying these effects articulates the complexity 
of this practice and opens this aspect of ‘clinical judge-
ment’ [59] to quantification and academic discussion. In 
particular, we have demonstrated that decision-making 
regarding the probability of the benefit of a medical 
intervention may involve, in addition to consideration 
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of the risk of the specific disease in question and trial-
based probabilities, consideration of initial impairment 
and age, and comorbidity-related death and impair-
ment threats. These factors are amenable to quantitative 
analysis, rather than being restricted to qualitative 
description. Such an analysis complements cost–benefit, 
and other external validity, considerations. 
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